| Malignant neoplasm of breast
Halaven vs Ibrance
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Halaven vs Ibrance with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIbrance has a higher rate of injection site reactions vs Halaven based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ibrance but not Halaven, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Halaven
Ibrance
At A Glance
IV infusion
Days 1 and 8 of a 21-day cycle
Microtubule dynamics inhibitor
Oral
Once daily (21 of 28 days)
CDK4/6 inhibitor
Indications
- Malignant neoplasm of breast
- Sarcoma
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast, Sarcoma 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle; reduce to 1.1 mg/m2 for mild hepatic impairment (Child-Pugh A) or moderate/severe renal impairment (CLcr 15-49 mL/min); reduce to 0.7 mg/m2 for moderate hepatic impairment (Child-Pugh B).
Malignant neoplasm of breast 125 mg orally once daily for 21 consecutive days followed by 7 days off to comprise a 28-day cycle; taken with food. Dose may be reduced to 100 mg or 75 mg for adverse reactions; patients with severe hepatic impairment (Child-Pugh C) start at 75 mg once daily.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) - Metastatic breast cancer Neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation
Most common (>=25%) - Liposarcoma and leiomyosarcoma Fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, pyrexia
Serious Febrile neutropenia, neutropenia
Postmarketing Lymphopenia, pancreatitis, hepatotoxicity, drug hypersensitivity, pneumonia, sepsis/neutropenic sepsis, interstitial lung disease, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=10%) Neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, dysgeusia
Serious Neutropenia, leukopenia, infections, anemia
Postmarketing Interstitial lung disease (ILD)/non-infectious pneumonitis, palmar-plantar erythrodysesthesia syndrome (PPES)
Pharmacology
Eribulin mesylate is a microtubule dynamics inhibitor that inhibits the growth phase of microtubules, sequesters tubulin into nonproductive aggregates, and exerts antimitotic effects via G2/M cell-cycle block and disruption of mitotic spindles, ultimately leading to apoptotic cell death after prolonged mitotic blockage.
Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6; it blocks progression of ER-positive breast cancer cells from G1 into S phase of the cell cycle, and in combination with antiestrogens decreases Rb protein phosphorylation, reduces E2F expression, and increases growth arrest.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Halaven
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Ibrance
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Halaven
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Ibrance
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Halaven
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Ibrance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HalavenView full Halaven profile
IbranceView full Ibrance profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.